Abstract
The Rorschach Test (RT) has historically informed descriptions of perceptual and thought disturbances, but its contemporary clinical applications require appraisal at the level of specific scores and purposes. Objective: This critical narrative review distinguishes historical observations, empirical assessment evidence, and the limited literature on change during treatment in psychotic-spectrum disorders. Methods: PubMed, supplementary Google Scholar searches, and reference lists were used to identify historical, clinical, psychometric, and treatment-related sources available through 30 June 2026. Heterogeneous designs and scoring systems were synthesized narratively without formal risk-of-bias grading or an exhaustive screening audit. Results: Contemporary support is variable-specific: the Comprehensive System Perceptual Thinking Index (PTI) has construct-validity support, whereas Rorschach Performance Assessment System (R-PAS) studies provide separate evidence concerning coding reliability and broader patient–nonpatient discrimination. These findings do not establish diagnostic accuracy for individual psychotic disorders. Treatment evidence includes a small longitudinal thought-disorder study, historical observations, a non-psychotic depression study, and a cross-sectional PTI study in a mixed psychotic-disorder/bipolar I sample. Cross-sectional associations cannot demonstrate within-patient responsiveness, and changes during treatment cannot establish medication-specific effects. Conclusions: The RT is not established as a stand-alone diagnostic or pharmacological-monitoring instrument. Selected measures of thought and perceptual disturbance may complement multimethod assessment, but incremental clinical utility and sensitivity to meaningful longitudinal change remain insufficiently established. Prospective controlled studies should assess symptoms, cognition, medication exposure, adverse effects, functioning, and quality of life alongside predefined Rorschach outcomes.